Mylan, Pfizer Barely Put Dent In EpiPen Antitrust MDL
Mylan NV and Pfizer Inc. on Monday largely failed to scale down multidistrict litigation over sky-high prices for emergency allergy treatment EpiPen, as a Kansas federal judge mostly refused to throw out wide-ranging consumer claims of...To view the full article, register now.
Already a subscriber? Click here to view full article